Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture

    March 2015 in “ ˜The œjournal of investigative dermatology/Journal of investigative dermatology ”
    Nicole L. Ward, Narasimharao Bhagathavula, Andrew Johnston, Sean M. Dawes, Wen Fu, Sylviane Lambert, Michael K. Dame, Roscoe L. Warner, Jóhann E. Guðjónsson, James Varani, James T. Elder
    TLDR Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
    The study investigated the mechanism behind erlotinib-induced skin inflammation using KC-Tie2 mice and human skin organ culture. It concluded that the inflammation was mediated by interleukin-1 (IL-1). Erlotinib treatment increased epidermal thickness and immune cell infiltration in KC-Tie2 mice, which was mitigated by the IL-1 receptor antagonist anakinra. Similarly, in human skin cultures, erlotinib-induced epidermal thickening and pro-inflammatory markers were blocked by anakinra. These findings suggested that IL-1 mediated the inflammatory effects of erlotinib, highlighting the potential of IL-1 inhibition to alleviate skin toxicity in patients undergoing EGFR inhibitor therapy.
    Discuss this study in the Community →